Overview

Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers
Phase:
Phase 1
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Voriconazole